Last update: Aug. 7, 2019
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
A thrombopoietin receptor agonist that increases platelet production. Indicated in the treatment of immune thrombopenic purpura, severe aplastic anemia and hepatitis C.
Administered orally once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (high percentage of protein binding and very low pKa) makes transfer to milk in significant amounts unlikely.
Its low oral bioavailability impedes transfer from breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
In addition, eltrombopag forms chelates with polyvalent ions such as calcium, which significantly reduces the drug’s possible absorption by the infant (EMA 2015)
Its use is authorized in Pediatrics from one year of age (EMA 2015).
We do not have alternatives for Eltrombopag.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.